MedTrace Logo

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

NCT00603356 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-09-27

No results posted yet for this study

Summary

This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.

Conditions

Interventions

DRUG

OSI-930 and erlotinib

OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity

Sponsors & Collaborators

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-04-30
Completion
2010-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603356 on ClinicalTrials.gov